Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - capsules - mavacamten 5 mg - mavacamten - camzyos is indicated for the treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - deucravacitinib - film coated tablets - deucravacitinib 6 mg - deucravacitinib - sotyktu is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Israel - English - Ministry of Health

bristol-myers squibb (israel) limited - belatacept 25 mg/ml - powder for concentrate for infusion - belatacept - nulojix, in combination with corticosteroids and mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. it is recommended to add an interleukin (il)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Israel - English - Ministry of Health

bristol-myers squibb (israel) limited - aripiprazole 10 mg - tablets - aripiprazole - abilify is indicated for the treatment of schizophrenia. and for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

Israel - English - Ministry of Health

bristol-myers squibb (israel) limited - aripiprazole 5 mg - tablets - aripiprazole - abilify is indicated for the treatment of schizophrenia. and for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

Israel - English - Ministry of Health

bristol-myers squibb (israel) limited - aripiprazole 15 mg - tablets - aripiprazole - abilify is indicated for the treatment of schizophrenia. and for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

Israel - English - Ministry of Health

bristol-myers squibb (israel) limited - aripiprazole 30 mg - tablets - aripiprazole - abilify is indicated for the treatment of schizophrenia. and for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited - paracetamol 10 mg/ml - solution for infusion - anilides - perfalgan is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by and urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 213 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,yervoy, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),yervoy, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),yervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),yervoy, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),yervoy in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.